Infliximab induces clinical resolution of sacroiliitis that coincides with increased circulating FOXP3+ T cells in a patient with IPEX syndrome-Reference-Cited by-同舟云学术

Infliximab induces clinical resolution of sacroiliitis that coincides with increased circulating FOXP3+ T cells in a patient with IPEX syndrome

Published:2020-10 Issue:5 Volume:87 Page:483-486
ISSN:1297-319X
Container-title:Joint Bone Spine
language:en
Short-container-title:Joint Bone Spine

Author:

Boschetti Gilles,Sarfati Marine,Fabien Nicole,Flourié Bernard,Lachaux Alain,Nancey Stéphane,Coury Fabienne

Publisher

Elsevier BV

Subject

Rheumatology

Reference18 articles.

1. The immune dysregulation, polyen-docrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3;Bennett;Nat Genet,2001

2. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study;Barzaghi;J Allergy Clin Immunol,2018

3. Familial autoimmune enteropathy with circulating anti-bullous pemphigoid antibodies and chronic autoimmune hepatitis;Lachaux;J Pediatr,1994

4. Flow cytometry characterization of epithelial cells released in the watery stools of a patient with autoimmune enteropathy;Lachaux;Am J Gastroenterol,1995

5. Autoimmune enteropathy in infants. Pathological study of the disease in two familial cases;Lachaux;Virchows Arch,1998

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted treatments for immune dysregulation in inborn errors of immunity;Exploration of Immunology;2024-04-23

2. FOXP3 deficiency, from the mechanisms of the disease to curative strategies;Immunological Reviews;2023-11-23

3. Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases;Pharmaceutics;2023-03-17

4. Precision medicine: The use of tailored therapy in primary immunodeficiencies;Frontiers in Immunology;2022-12-08

5. The role of TNF-α and anti-TNF-α agents in the immunopathogenesis and management of immune dysregulation in primary immunodeficiency diseases;Immunopharmacology and Immunotoxicology;2022-01-04